Abaffy Tatjana, Möller Mecker, Riemer Daniel D, Milikowski Clara, Defazio R Anthony
Molecular and Cellular Pharmacology, University of Miami, Miami, Fl, USA.
J Cancer Sci Ther. 2011;3(6):140-144. doi: 10.4172/1948-5956.1000076.
Melanoma is the most serious form of skin cancer. The quest for melanoma diagnostic biomarkers is paramount since early detection of melanoma and surgical excision represent the only effective treatment of this capricious disease. Our recent study tested the hypothesis that melanoma forms a unique volatile signature that is different than control, healthy tissue. Here, we are reporting a case study, the analysis of the volatile metabolic signature of a malignant melanoma using matched, non-neoplastic skin tissue from the same patient as a control. This is a significant improvement in the methodology, since it is well known that diet, skin type, genetic background, age, sex and environment all contribute to individual variation in the skin volatile signature. In the present study, we have identified 32 volatile compounds; 9 volatile compounds were increased in melanoma when compared to normal skin and 23 volatile compounds were detected only in melanoma and not in normal skin. Out of these 32 compounds, 10 have been reported previously by our group, thus confirming our results and adding additional confidence in our untargeted metabolomics approach for detection of melanoma biomarkers.
黑色素瘤是最严重的皮肤癌形式。由于黑色素瘤的早期检测和手术切除是治疗这种多变疾病的唯一有效方法，因此寻找黑色素瘤诊断生物标志物至关重要。我们最近的研究检验了这样一个假设，即黑色素瘤形成一种独特的挥发性特征，与对照的健康组织不同。在此，我们报告一项病例研究，即使用来自同一患者的匹配非肿瘤皮肤组织作为对照，分析恶性黑色素瘤的挥发性代谢特征。这在方法学上是一个显著的改进，因为众所周知，饮食、皮肤类型、遗传背景、年龄、性别和环境都会导致皮肤挥发性特征的个体差异。在本研究中，我们鉴定出32种挥发性化合物；与正常皮肤相比，黑色素瘤中有9种挥发性化合物增加，23种挥发性化合物仅在黑色素瘤中检测到，而在正常皮肤中未检测到。在这32种化合物中，我们团队之前已报告过10种，从而证实了我们的结果，并增强了我们对用于检测黑色素瘤生物标志物的非靶向代谢组学方法的信心。
